Skip to content
Screener

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$40.6M
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$128.01M
Alumis Inc. logo
Alumis Inc.ALMS
$346.99M
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$2.53M+314%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$14.42M-94.1%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.55B-54.2%
Enterprise value$1.36B-57.1%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 8:55 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001821586-26-000007
(in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Issuance of Class A Ordinary Shares, net of transaction costs6,007
Proceeds from options exercised under the MoonLake Immunotherapeutics 2022 Equity Incentive Plan170
Proceeds from options exercised under Employee Stock Option Plan100
Net cash flow provided by financing activities30,64473,122
Effect of movements in exchange rates on cash held(483)(88)
Net change in cash and cash equivalents(36,027)91,140
Cash and cash equivalents, beginning of period334,517180,426
Cash and cash equivalents, end of period$298,490$271,566

Item 1. Financial Statements (Unaudited)

FAQ

What is MoonLake Immunotherapeutics's financing cash flow?
MoonLake Immunotherapeutics (MLTX) reported financing cash flow of $30.64M in Q1 2026.
How has MoonLake Immunotherapeutics's financing cash flow changed year-over-year?
MoonLake Immunotherapeutics's financing cash flow decreased by 58.1% year-over-year, from $73.12M to $30.64M.
What is the long-term trend for MoonLake Immunotherapeutics's financing cash flow?
Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's financing cash flow has grown at a 19.5% compound annual growth rate (CAGR), from $71.53M to $146M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about MoonLake Immunotherapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude